ArticleCancer diagnosis & prognosis
Baseline Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival in PD-L1-positive Advanced Triple-negative Breast Cancer With Immune-checkpoint-inhibitor Treatment.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Immune checkpoint inhibitors (ICIs) have improved clinical outcomes in patients with advanced triple-negative breast cancer (TNBC); however, substantial heterogeneity exists in treatment durability and survival. Simple blood-based immune markers may provide prognostic information; however, their clinical relevance in ICI-treated TNBC remain unclear. Patients and Methods: We conducted a retrospective single-center study of patients with advanced TNBC treated with ICIs, including atezolizumab or pembrolizumab. Baseline peripheral immune markers - absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR) - were evaluated prior to treatment initiation. Time-to-treatment failure (TTF) and overall survival (OS) were analyzed using the Kaplan-Meier method and Cox proportional hazards model. Results: A total of 43 patients were included. In the Kaplan-Meier analysis, high baseline NLR was significantly associated with both shorter TTF and OS. Low baseline ALC was significantly associated with shorter TTF but not with OS. In the multivariate Cox proportional hazards analysis of TTF, no baseline clinical or immune parameters were identified as independent prognostic factors. In contrast, multivariate analysis for OS demonstrated that high baseline NLR was the only independent prognostic factor. Conclusion: NLR was independently associated with OS, suggesting it functions as a prognostic marker of systemic inflammatory and immune balance. In contrast, ALC was associated with treatment durability but not long-term survival, indicating its relevance to treatment tolerance rather than survival outcomes. These findings highlight the clinical utility of simple blood-based immune markers for risk stratification in ICI-treated TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.